Fig. 3From: Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter studya Independent review committee-assessed progression-free survival. b Independent review committee-assessed duration of responseBack to article page